Proteases de Leishmania: novos alvos para o desenvolvimento racional de fármacos

Detalhes bibliográficos
Autor(a) principal: Silva-López,Raquel Elisa da
Data de Publicação: 2010
Tipo de documento: Artigo
Idioma: por
Título da fonte: Química Nova (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-40422010000700022
Resumo: Leishmania causes tegumental and visceral diseases called leishmaniasis. Disease control is possible interrupting the transmission cycle, but HIV co-infection, chemotheraphy toxicity and lack of a vaccine are paramount difficulties. So, is necessary to study new Leishmania molecules and investigate the possibility to develop rational drugs using these molecules as targets. Leishmania express many peptidases during their life, and cysteine are the most abundant protease and many inhibitors were developed but failed to kill parasites. On the other hand, inhibitors of serine proteases killed promastigotes, indicating the possibility of these enzymes to be important targets in the development of anti-Leishmania drugs.
id SBQ-3_daa8bac958a197c87f6419ff9a8c7a4f
oai_identifier_str oai:scielo:S0100-40422010000700022
network_acronym_str SBQ-3
network_name_str Química Nova (Online)
repository_id_str
spelling Proteases de Leishmania: novos alvos para o desenvolvimento racional de fármacosproteasesLeishmaniachemotheraphyLeishmania causes tegumental and visceral diseases called leishmaniasis. Disease control is possible interrupting the transmission cycle, but HIV co-infection, chemotheraphy toxicity and lack of a vaccine are paramount difficulties. So, is necessary to study new Leishmania molecules and investigate the possibility to develop rational drugs using these molecules as targets. Leishmania express many peptidases during their life, and cysteine are the most abundant protease and many inhibitors were developed but failed to kill parasites. On the other hand, inhibitors of serine proteases killed promastigotes, indicating the possibility of these enzymes to be important targets in the development of anti-Leishmania drugs.Sociedade Brasileira de Química2010-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-40422010000700022Química Nova v.33 n.7 2010reponame:Química Nova (Online)instname:Sociedade Brasileira de Química (SBQ)instacron:SBQ10.1590/S0100-40422010000700022info:eu-repo/semantics/openAccessSilva-López,Raquel Elisa dapor2010-09-27T00:00:00Zoai:scielo:S0100-40422010000700022Revistahttps://www.scielo.br/j/qn/ONGhttps://old.scielo.br/oai/scielo-oai.phpquimicanova@sbq.org.br1678-70640100-4042opendoar:2010-09-27T00:00Química Nova (Online) - Sociedade Brasileira de Química (SBQ)false
dc.title.none.fl_str_mv Proteases de Leishmania: novos alvos para o desenvolvimento racional de fármacos
title Proteases de Leishmania: novos alvos para o desenvolvimento racional de fármacos
spellingShingle Proteases de Leishmania: novos alvos para o desenvolvimento racional de fármacos
Silva-López,Raquel Elisa da
proteases
Leishmania
chemotheraphy
title_short Proteases de Leishmania: novos alvos para o desenvolvimento racional de fármacos
title_full Proteases de Leishmania: novos alvos para o desenvolvimento racional de fármacos
title_fullStr Proteases de Leishmania: novos alvos para o desenvolvimento racional de fármacos
title_full_unstemmed Proteases de Leishmania: novos alvos para o desenvolvimento racional de fármacos
title_sort Proteases de Leishmania: novos alvos para o desenvolvimento racional de fármacos
author Silva-López,Raquel Elisa da
author_facet Silva-López,Raquel Elisa da
author_role author
dc.contributor.author.fl_str_mv Silva-López,Raquel Elisa da
dc.subject.por.fl_str_mv proteases
Leishmania
chemotheraphy
topic proteases
Leishmania
chemotheraphy
description Leishmania causes tegumental and visceral diseases called leishmaniasis. Disease control is possible interrupting the transmission cycle, but HIV co-infection, chemotheraphy toxicity and lack of a vaccine are paramount difficulties. So, is necessary to study new Leishmania molecules and investigate the possibility to develop rational drugs using these molecules as targets. Leishmania express many peptidases during their life, and cysteine are the most abundant protease and many inhibitors were developed but failed to kill parasites. On the other hand, inhibitors of serine proteases killed promastigotes, indicating the possibility of these enzymes to be important targets in the development of anti-Leishmania drugs.
publishDate 2010
dc.date.none.fl_str_mv 2010-01-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-40422010000700022
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-40422010000700022
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv 10.1590/S0100-40422010000700022
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Química
publisher.none.fl_str_mv Sociedade Brasileira de Química
dc.source.none.fl_str_mv Química Nova v.33 n.7 2010
reponame:Química Nova (Online)
instname:Sociedade Brasileira de Química (SBQ)
instacron:SBQ
instname_str Sociedade Brasileira de Química (SBQ)
instacron_str SBQ
institution SBQ
reponame_str Química Nova (Online)
collection Química Nova (Online)
repository.name.fl_str_mv Química Nova (Online) - Sociedade Brasileira de Química (SBQ)
repository.mail.fl_str_mv quimicanova@sbq.org.br
_version_ 1750318111103385600

Registros relacionados